CO2021001046A2 - Anticuerpos procoagulantes mejorados - Google Patents
Anticuerpos procoagulantes mejoradosInfo
- Publication number
- CO2021001046A2 CO2021001046A2 CONC2021/0001046A CO2021001046A CO2021001046A2 CO 2021001046 A2 CO2021001046 A2 CO 2021001046A2 CO 2021001046 A CO2021001046 A CO 2021001046A CO 2021001046 A2 CO2021001046 A2 CO 2021001046A2
- Authority
- CO
- Colombia
- Prior art keywords
- binding
- fixa
- factor
- activated form
- antigen
- Prior art date
Links
- 239000003805 procoagulant Substances 0.000 title abstract 2
- 108010048049 Factor IXa Proteins 0.000 abstract 5
- 108010014173 Factor X Proteins 0.000 abstract 5
- 108010076282 Factor IX Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 2
- 229960004222 factor ix Drugs 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000013831 Coagulation factor IX Human genes 0.000 abstract 1
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 206010053567 Coagulopathies Diseases 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 229940105774 coagulation factor ix Drugs 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
RESUMEN La presente invención se refiere a anticuerpos procoagulantes multiespecíficos capaces de unirse al Factor IX (FIX) de coagulación y/o la forma activada de este Factor IXa (FIXa), y Factor X (FX) y/o la forma activada de este Factor Xa (FXa) y que promueven la activación del FX por parte del FIXa, anticuerpos que se unen a sus epítopos o partes de estos y métodos y composición para tratar sujetos que padecen una coagulopatía tal como hemofilia A, así como también kits, métodos de fabricación y métodos de uso. 1. Un anticuerpo multiespecífico o fragmento de unión al antígeno de este capaz de estimular la actividad enzimática del FIXa hacia el FX que comprende un primer sitio de unión al antígeno capaz de unirse al FIX (SEQ ID NO:1) y/o la forma activada de este (FIXa), y un segundo sitio de unión al antígeno capaz de unirse al FX (SEQ ID NO:2) y/o la forma activada de este (FXa).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018097834 | 2018-08-01 | ||
| CN2018099339 | 2018-08-08 | ||
| EP18193191 | 2018-09-07 | ||
| PCT/EP2019/070628 WO2020025672A1 (en) | 2018-08-01 | 2019-07-31 | Improved procoagulant antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021001046A2 true CO2021001046A2 (es) | 2021-04-30 |
Family
ID=67480228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0001046A CO2021001046A2 (es) | 2018-08-01 | 2021-01-29 | Anticuerpos procoagulantes mejorados |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230058721A1 (es) |
| EP (1) | EP3830135A1 (es) |
| JP (3) | JP6761142B1 (es) |
| KR (2) | KR20210091839A (es) |
| CN (3) | CN112513096B (es) |
| AU (1) | AU2019313550B2 (es) |
| BR (1) | BR112021000823A2 (es) |
| CA (1) | CA3113797A1 (es) |
| CL (1) | CL2021000186A1 (es) |
| CO (1) | CO2021001046A2 (es) |
| IL (1) | IL280239A (es) |
| MA (1) | MA53322A (es) |
| MX (1) | MX2021001064A (es) |
| PE (1) | PE20211399A1 (es) |
| PH (1) | PH12021550117A1 (es) |
| SG (1) | SG11202100418PA (es) |
| TW (1) | TWI716059B (es) |
| WO (1) | WO2020025672A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023512089A (ja) * | 2020-01-30 | 2023-03-23 | ノヴォ ノルディスク アー／エス | 二重特異性第ｖｉｉｉ因子模倣抗体 |
| KR20230130561A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법 |
| KR20230130560A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 주 1회 투여 방법 |
| KR20230130558A (ko) | 2022-03-02 | 2023-09-12 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Fviii 모방 이중특이적 항체의 월 1회 투여 방법 |
| WO2024008904A2 (en) | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| DE69830901T2 (de) * | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| US7297336B2 (en) | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
| AU2003271186A1 (en) * | 2003-10-14 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| WO2006109592A1 (ja) * | 2005-04-08 | 2006-10-19 | Chugai Seiyaku Kabushiki Kaisha | 血液凝固第viii因子の機能代替抗体 |
| MX355060B (es) * | 2010-11-17 | 2018-04-03 | Chugai Pharmaceutical Co Ltd | Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea. |
| WO2013167669A1 (en) * | 2012-05-10 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| US20160297892A1 (en) * | 2013-11-07 | 2016-10-13 | Novo Nordisk A/S | Novel Methods and Antibodies for Treating Coagulapathy |
| TWI700300B (zh) * | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| AU2016248817A1 (en) * | 2015-04-17 | 2017-08-17 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
| CR20190297A (es) * | 2016-11-23 | 2019-11-01 | Bioverativ Therapeutics Inc | Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x |
| BR112019015611A2 (pt) | 2017-02-01 | 2020-03-17 | Novo Nordisk A/S | Anticorpos pró-coagulantes |
| US11220554B2 (en) * | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
-
2019
- 2019-07-31 AU AU2019313550A patent/AU2019313550B2/en active Active
- 2019-07-31 CN CN201980050877.2A patent/CN112513096B/zh active Active
- 2019-07-31 PE PE2021000121A patent/PE20211399A1/es unknown
- 2019-07-31 SG SG11202100418PA patent/SG11202100418PA/en unknown
- 2019-07-31 EP EP19746091.8A patent/EP3830135A1/en active Pending
- 2019-07-31 MX MX2021001064A patent/MX2021001064A/es unknown
- 2019-07-31 CA CA3113797A patent/CA3113797A1/en active Pending
- 2019-07-31 KR KR1020217022278A patent/KR20210091839A/ko not_active Application Discontinuation
- 2019-07-31 KR KR1020217004977A patent/KR102382743B1/ko active IP Right Grant
- 2019-07-31 WO PCT/EP2019/070628 patent/WO2020025672A1/en unknown
- 2019-07-31 JP JP2020506232A patent/JP6761142B1/ja active Active
- 2019-07-31 CN CN202310981355.2A patent/CN117384296A/zh active Pending
- 2019-07-31 BR BR112021000823-3A patent/BR112021000823A2/pt unknown
- 2019-07-31 MA MA053322A patent/MA53322A/fr unknown
- 2019-07-31 CN CN202310977964.0A patent/CN117343188A/zh active Pending
- 2019-08-01 TW TW108127371A patent/TWI716059B/zh active
-
2020
- 2020-03-04 JP JP2020036964A patent/JP7094314B2/ja active Active
-
2021
- 2021-01-15 PH PH12021550117A patent/PH12021550117A1/en unknown
- 2021-01-18 IL IL280239A patent/IL280239A/en unknown
- 2021-01-22 CL CL2021000186A patent/CL2021000186A1/es unknown
- 2021-01-29 CO CONC2021/0001046A patent/CO2021001046A2/es unknown
- 2021-11-10 US US17/522,949 patent/US20230058721A1/en active Pending
-
2022
- 2022-03-25 JP JP2022050042A patent/JP7355874B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020530449A (ja) | 2020-10-22 |
| CA3113797A1 (en) | 2020-02-06 |
| JP2022084858A (ja) | 2022-06-07 |
| BR112021000823A2 (pt) | 2021-04-13 |
| CL2021000186A1 (es) | 2021-07-02 |
| KR20210091839A (ko) | 2021-07-22 |
| WO2020025672A9 (en) | 2020-04-23 |
| AU2019313550A1 (en) | 2021-02-04 |
| JP7094314B2 (ja) | 2022-07-01 |
| MA53322A (fr) | 2021-11-10 |
| CN112513096B (zh) | 2023-08-25 |
| CN117343188A (zh) | 2024-01-05 |
| SG11202100418PA (en) | 2021-02-25 |
| CN117384296A (zh) | 2024-01-12 |
| CN112513096A (zh) | 2021-03-16 |
| IL280239A (en) | 2021-03-25 |
| AU2019313550B2 (en) | 2024-02-08 |
| PH12021550117A1 (en) | 2021-10-04 |
| JP7355874B2 (ja) | 2023-10-03 |
| KR20210040389A (ko) | 2021-04-13 |
| US20230058721A1 (en) | 2023-02-23 |
| MX2021001064A (es) | 2021-04-12 |
| WO2020025672A1 (en) | 2020-02-06 |
| JP6761142B1 (ja) | 2020-09-23 |
| TW202007696A (zh) | 2020-02-16 |
| JP2020115863A (ja) | 2020-08-06 |
| TWI716059B (zh) | 2021-01-11 |
| KR102382743B1 (ko) | 2022-04-12 |
| PE20211399A1 (es) | 2021-07-27 |
| EP3830135A1 (en) | 2021-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021001046A2 (es) | Anticuerpos procoagulantes mejorados | |
| CO2019008461A2 (es) | Anticuerpos procoagulantes | |
| CL2019001372A1 (es) | Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x. | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| CL2019003520A1 (es) | Anticuerpos que se unen específicamente a pd-1 y procedimientos de uso. | |
| CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
| CY1124118T1 (el) | Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων | |
| CY1124747T1 (el) | Ανθρωπινα αντισωματα σε pd-1 | |
| PE20181049A1 (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia | |
| UY37591A (es) | Conjugados de fármaco anticuerpo | |
| ES2617920T3 (es) | Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2 | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| EA201691470A1 (ru) | Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека | |
| CY1122132T1 (el) | Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| ES2670668T3 (es) | Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica | |
| CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| EA202191736A1 (ru) | Комбинированная терапия hbv | |
| EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
| EA202190647A1 (ru) | Антитела к klrg1 | |
| BR112022001199A2 (pt) | Imunoterapia para poliomavírus | |
| AR114539A1 (es) | Anticuerpos procoagulantes mejorados | |
| EA201891196A1 (ru) | Cgrp-антитела и их применение | |
| AR111016A1 (es) | Anticuerpos procoagulantes |